logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Stemcentrx, Inc.


USPTO Granted Patents = 18

% Expired Patents = 72.2


Forward Citations = 138

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Scott J Dylla (18 out of 50 patents)

silverMedal Orit Foord (17 out of 78 patents)

bronzeMedal Robert A Stull (17 out of 44 patents)

4.  Laura Saunders (14 out of 38 patents)

5.  Michael Torgov (14 out of 49 patents)

6.  Hui Shao (14 out of 36 patents)

7.  David Y Liu (14 out of 108 patents)

8.  Jeffrey Traer Bernstein (1 out of 184 patents)

9.  Alexandra Leida Liana Lazetic (1 out of 10 patents)

10.  Alex Bankovich (1 out of 5 patents)

11.  Puja Sapra (1 out of 9 patents)

12.  Johannes Hampl (1 out of 5 patents)

13.  Wade C Anderson (1 out of 4 patents)

14.  Saiyou Ohshima (1 out of 2 patents)

15.  Kiran Khandke (1 out of 7 patents)


18 patents:

1. 9458231 - Modulators and methods of use (2016-10-04),
2. 9409995 - PTK7 modulators and methods of use (2016-08-09),
3. 9381205 - Anti-EFNA4 antibody-drug conjugates (2016-07-05),
4. 9358304 - Methods of making DLL3 antibody drug conjugates (2016-06-07),
5. 9353182 - Anti-DLL3 antibodies (2016-05-31),
6. 9352051 - Kits containing DLL3 antibody drug conjugates (2016-05-31),
7. 9345784 - Methods of delivering DLL3 antibody drug conjugates (2016-05-24),
8. 9334318 - Multivalent DLL3 antibodies (2016-05-10),
9. 9320812 - Modulators and methods of use (2016-04-26),
10. 9173959 - Anti-DLL3 antibody drug conjugates (2015-11-03),
11. 9155803 - Anti-DLL3 antibody drug conjugates and methods of use (2015-10-13),
12. 9133271 - Anti-DLL3 antibody drug conjugates and methods of use (2015-09-15),
13. 9107961 - Anti-DLL3 antibody drug conjugates for treating cancer (2015-08-18),
14. 9090683 - Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies (2015-07-28),
15. 9089617 - Anti-DLL3 antibody drug conjugates (2015-07-28),
Company Overview
Stemcentrx, Inc. is a biotechnology company based in South San Francisco, California, specializing in the development of innovative therapies for cancer treatment. The company focuses on harnessing the power of stem cell biology to create targeted therapies that aim to improve patient outcomes. Stemcentrx is known for its research in monoclonal antibodies and other biologics, working to address unmet medical needs in oncology through advanced scientific approaches and cutting-edge technology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

18 Patents

#74 in South San Francisco, CA

#4,284 in California

#17,952 in US

#34,187 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Stemcentrx, Inc.

Forward Citations = 138

17 inventors:

goldMedal Scott J Dylla (18 out of 50 patents)

silverMedal Orit Foord (17 out of 78 patents)

bronzeMedal Robert A Stull (17 out of 44 patents)

4.  Laura Saunders (14 out of 38 patents)

5.  Michael Torgov (14 out of 49 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Stemcentrx, Inc.. Retrieved from https://idiyas.com/company/stemcentrx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…